CN Patent

CN111388419A — 阿瑞匹坦乳剂

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2020-07-10 · 6y expired

What this patent protects

本发明公开了一种稳定的注射用阿瑞匹坦乳剂制剂，包含：阿瑞匹坦，乳化剂、助乳化剂、注射用油、张力调节剂、pH调节剂和注射用水。其中，乳化剂与阿瑞匹坦的重量比为12:1～14:1，乳化剂的含量为9wt％～10wt％，pH范围为8.0～9.5。该药物制剂为稳定的水包油乳剂，具有较小的粒径及良好的物理稳定性，适用于非口服的用于经受高度或中度致吐癌症化疗患者的治疗。

USPTO Abstract

本发明公开了一种稳定的注射用阿瑞匹坦乳剂制剂，包含：阿瑞匹坦，乳化剂、助乳化剂、注射用油、张力调节剂、pH调节剂和注射用水。其中，乳化剂与阿瑞匹坦的重量比为12:1～14:1，乳化剂的含量为9wt％～10wt％，pH范围为8.0～9.5。该药物制剂为稳定的水包油乳剂，具有较小的粒径及良好的物理稳定性，适用于非口服的用于经受高度或中度致吐癌症化疗患者的治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN111388419A
Jurisdiction
CN
Classification
—
Expires
2020-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.